Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 6/20 | 0.85 |
| ▸ | HPGD | P15428 | 4/20 | 0.85 |
| ▸ | GLA | P06280 | 3/20 | 0.85 |
| ▸ | GAA | P10253 | 3/20 | 0.85 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.85 |
| ▸ | TSHR | P16473 | 1/20 | 0.85 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.77 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.61 |
| ▸ | ATM | Q13315 | 2/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.59 |
| ▸ | ACP1 | P24666 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | DCTPP1 | Q9H773 | 1/20 | 0.58 |
| ▸ | GBA1 | P04062 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1090785 | 0.92 | L3MBTL1 (1.00) | L3MBTL1HPGDGLAGAAHSD17B10 | |
| SCHEMBL1091130 | 0.92 | L3MBTL1 (1.00) | L3MBTL1HPGDGLAGAAHSD17B10 | |
| SCHEMBL3640898 | 0.92 | L3MBTL1 (0.72) | L3MBTL1HPGDGLAGAAHSD17B10 | |
| SCHEMBL30454930 | 0.91 | L3MBTL1 (0.97) | L3MBTL1HPGDGLAGAAHSD17B10 | |
| SCHEMBL11738679 | 0.91 | L3MBTL1 (0.97) | L3MBTL1HPGDGLAGAAHSD17B10 | |
| SCHEMBL3641129 | 0.91 | L3MBTL1 (0.74) | L3MBTL1HPGDGLAGAAHSD17B10 | |
| SCHEMBL3675539 | 0.82 | L3MBTL1 (0.80) | L3MBTL1HPGDGLAGAAHSD17B10 | |
| SCHEMBL14504432 | 0.82 | LMNA (0.60) | L3MBTL1HPGDGLAGAAHSD17B10 | |
| SCHEMBL3642537 | 0.82 | L3MBTL1 (0.78) | L3MBTL1HPGDGLAGAAHSD17B10 | |
| Hydrochloric Acid SCHEMBL3670729 | 0.81 | L3MBTL1 (0.78) | L3MBTL1HPGDGLAGAAHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100317607-A1 | USE OF COMPOUNDS FOR PREPARING ANTI-TUBERCULOSIS AGENTS | INFECTIOUS DISEASE RESEARCH INSTITUTE (US) | 2010-12-16 | — | — | US | claimed |
| CN-101784276-A | Use of compounds for the preparation of antituberculosis agents | SUMMIT CORP PLC | 2010-07-21 | — | — | CN | claimed |
| US-20100317607-A1 | USE OF COMPOUNDS FOR PREPARING ANTI-TUBERCULOSIS AGENTS | INFECTIOUS DISEASE RESEARCH INSTITUTE (US) | 2010-12-16 | — | — | US | disclosed |
| CN-101784276-A | Use of compounds for the preparation of antituberculosis agents | SUMMIT CORP PLC | 2010-07-21 | — | — | CN | disclosed |
| EP-2173346-A2 | USE OF COMPOUNDS FOR PREPARING ANTI-TUBERCULOSIS AGENTS | Summit Corporation Plc (GB) | 2010-04-14 | — | — | EP | disclosed |
| WO-2009001060-A2 | USE OF COMPOUNDS FOR PREPARING ANTI-TUBERCULOSIS AGENTS | SUMMIT CORPORATION PLC (GB) | 2008-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317607-A1 | USE OF COMPOUNDS FOR PREPARING ANTI-TUBERCULOSIS AGENTS | TPX2, DCXR, RRM2 | L3MBTL1 3143/4885HPGD 953/4885GLA 636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.